Document Detail


Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells.
MedLine Citation:
PMID:  16713283     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oncostatin M (OSM), an IL-6 family cytokine, has previously been shown to increase migration of several breast cancer cell lines in vitro. Our studies report additional effects of OSM treatment on the human breast carcinoma cell line T-47D. OSM treatment alters T-47D cell morphology from a normal epithelial phenotype to a mesenchymal-like phenotype that is associated with cell detachment from substratum. These effects are also seen with H3922 human breast cancer cells. OSM treatment of T-47D cells for 5-8 days leads to a three-fold increase in cell detachment. OSM-induced detachment of T-47D cells is blocked by the protein kinase inhibitors UO126 and bisindolylmaleimide, indicating a role for MAP kinases and protein kinase C in OSM signaling events that regulate cell detachment. T-47D cells induced to detach by OSM have a reduced capacity to re-adhere to laminin in comparison to other extracellular matrix components. Detached multi-cell aggregates of T-47D cells are viable, whereas detached single cells appear apoptotic. In addition, OSM treatment induces the secretion of the lysosomal proteases cathepsins D and L from T-47D cells, which have been implicated in invasion and metastasis. Importantly, OSM-treated T-47D cells show a 250% increase in invasive capacity as measured by the Matrigel invasion chamber assay. Collectively, these data demonstrate that OSM induces a motile/invasive phenotype in T-47D cells in vitro, and suggest that OSM may enhance metastasis in vivo. Our results suggest that OSM itself may be a valid therapeutic target.
Authors:
Cheryl L Jorcyk; Ryan G Holzer; Randall E Ryan
Related Documents :
9231173 - Basaloid squamous cell carcinoma of the maxilla.
16928983 - Phenotype-based screening of mechanistically annotated compounds in combination with ge...
24120843 - A method for high purity sorting of rare cell subsets applied to tdc.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2006-05-19
Journal Detail:
Title:  Cytokine     Volume:  33     ISSN:  1043-4666     ISO Abbreviation:  Cytokine     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-06-07     Completed Date:  2006-08-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9005353     Medline TA:  Cytokine     Country:  United States    
Other Details:
Languages:  eng     Pagination:  323-36     Citation Subset:  IM    
Affiliation:
Department of Biology, Boise State University, 1910 University Drive, Science-Nursing Building, Room 227, Boise, ID 83725, USA. cjorcyk@boisestate.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / pharmacology*
Apoptosis / physiology
Breast Neoplasms / enzymology,  pathology*
Cell Adhesion / physiology
Cell Line, Tumor
Cytokines / physiology*
Female
Humans
Neoplasm Invasiveness / pathology
Neoplasm Metastasis / pathology
Oncostatin M
Grant Support
ID/Acronym/Agency:
P20RR1645R/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cytokines; 0/OSM protein, human; 106956-32-5/Oncostatin M

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not w...
Next Document:  Evolution of cytokine responses: IL-1beta directly affects intracellular Ca2+ concentration of teleo...